HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Listed as NCT04618367, this NA trial focuses on Carcinoma, Hepatocellular and Liver Neoplasms and remains completed. Sponsored by Second Affiliated Hospital of Guangzhou Medical University, it has been updated 6 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2024 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Feb 2023 — Apr 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Second Affiliated Hospital of Guangzhou Medical University
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Guangzhou, China